The potential economic value of a human norovirus vaccine for the United States

Sarah M. Bartsch, Benjamin A. Lopman, Aron J. Hall, Umesh D. Parashar, Bruce Y. Lee

Research output: Contribution to journalArticlepeer-review


Vaccines against human norovirus are currently under development. We developed a simulation model to determine their potential economic value. Vaccination prevented 100-6125 norovirus gastroenteritis cases per 10,000 vaccinees. Low vaccine cost (≤$50) garnered cost-savings and a more expensive vaccine led to costs per case averted comparable to other vaccines. In the US, vaccination could avert approximately 1.0-2.2 million cases (efficacy 50%, 12. month duration), costing an additional $400 million to $1.0 billion, but could save ≤$2.1 billion (48. month duration). Human norovirus vaccination can offer economic value while averting clinical outcomes, depending on price, efficacy, and protection duration.

Original languageEnglish (US)
Pages (from-to)7097-7104
Number of pages8
Issue number49
StatePublished - Nov 19 2012
Externally publishedYes


  • Economics
  • Norovirus
  • Vaccine

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases


Dive into the research topics of 'The potential economic value of a human norovirus vaccine for the United States'. Together they form a unique fingerprint.

Cite this